Investor Eye: Sofinnova Speaks On Deal Execution, Managing Expertise And what’s In Store For The Future
Executive Summary
Times may look bleak for medtech investment. Public markets are down and VC is shyer than ever about spending money. Medtech Insight spoke to Antoine Papiernik of Sofinnova Partners to learn more about the path forward.
You may also be interested in...
Execs On The Move, January 2023: Spun-Off GE Healthcare Names Board, Officers
An interactive view of medtech executive changes from the month of January 2023, including GE Healthcare's new leadership as a standalone company.
Axogen, Dario Health, Biobeat, Immunexpress All Weigh In On 2022 And What Will Succeed In 2023
Medtech Insight was invited to ask questions at a roundtable event organized by Russo Partners to review the major medtech industry trends of 2022 and what to expect in 2023.
Snapshot: January Highlights
A selection of articles you may have missed from January 2023, covering the FDA's approach to gene therapies and their long-term implications, the rise (and possible fall) of Chinese companies' efforts in drug development and the ongoing consideration of the 'E' in ESG.